Skip to main content
Log in

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

  • Review
  • DNA Topoisomerase, Chemotherapy
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Berger NA, Chatterjee S, Schmotzer JA, Helms SR (1991) Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci USA 88: 8740–8743

    Google Scholar 

  2. Berrios M, Osheroff N, Fisher PA (1985) In situ localization of DNA topoisomerase II, a major polypeptide component of theDrosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82: 4142–4146

    Google Scholar 

  3. Bertrand R, Kerrigan D, Sarang M, Pommier Y (1991) Cell death induced by topoisomerase inhibitors: role of calcium in mammalian cells. Biochem Pharmacol 42: 77–85

    Google Scholar 

  4. Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y (1991) Differential induction of secondary fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplifiedc-myc expression. Cancer Res 51: 6280–6285

    Google Scholar 

  5. Brill SJ, Sternglanz R (1988) Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants. Cell 54: 403–411

    Google Scholar 

  6. Brill SJ, DiNardo S, Voelkel-Meiman K, Sternglanz R (1987) Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA [published erratum appears in Nature 326(6115): 812]. Nature 326: 414–416

    Google Scholar 

  7. Bugg BY, Danks MK, Beck WT, Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88: 7654–7658

    Google Scholar 

  8. Bullock P, Champoux JJ, Botchan M (1985) Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination. Science 230: 954–958

    Google Scholar 

  9. Capranico G, Kohn KW, Pommier Y (1990) Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 18: 6611–6619

    Google Scholar 

  10. Capranico G, Zunino F, Kohn KW, Pommier Y (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA affinity and cytotoxicity. Biochemistry 29: 562–569

    Google Scholar 

  11. Champoux JJ (1990) Mechanistic aspects of type-I topoisomerases. In: Wang JC, Cozzarelli NR (eds) topology and its biological effects. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 217–242

    Google Scholar 

  12. Chang J-Y, Han F-S, Liu S-Y, Wang Z-Q, Lee K-H, Cheng Y-C (1991) Effect of 4-beta-arylamino derivatives of 4′-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res 51: 1755–1759

    Google Scholar 

  13. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039–6044

    Google Scholar 

  14. Chow KC, King CK, Ross WE (1988) Abrogation of etoposide-mediated cytotoxicity by cycloheximide. Biochem Pharmacol 37: 1117–1122

    Google Scholar 

  15. Chung TDY, Drake FH, Tan KB, Per SR, Crooke S, Mirabelli CK (1989) Characterization and immunological identification of cDNA clones encoding two human topoisomerase II isoenzymes. Proc Natl Acad Sci USA 86: 9431–9435

    Google Scholar 

  16. Crissman HA, Gadbois DM, Tobey RA, Bradbury EM (1991) Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc Natl Acad Sci USA 88: 7580–7584

    Google Scholar 

  17. D'Arpa P, Machlin PS, Ratrie H III, Rothfield NF, Cleveland DW, Earnshaw WC (1988) cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 85: 2543–2547

    Google Scholar 

  18. D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919–6924

    Google Scholar 

  19. DiNardo S, Voelkel K, Sternglanz R (1984) DNA topoisomerase II mutant ofSaccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 81: 2616–2620

    Google Scholar 

  20. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST, et al (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 262: 16739–16747

    Google Scholar 

  21. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154–8160

    Google Scholar 

  22. Duguet M, Lavenot C, Harper F, Mirambeau G, De Recondo AM (1983) DNA topoisomerase from rat liver: physiological variations. Nucleic Acids Res 11: 1059–1075

    Google Scholar 

  23. Earnshaw WC, Halligan B, Cooke CA, Heck MM, Liu LF (1985) Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol 100: 1706–1715

    Google Scholar 

  24. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SC (1984) Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81: 6958–6962

    Google Scholar 

  25. Fosse P, Rene B, Le Bret M, Paoletti C, Saucier J-M (1991) Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 19: 2861–2868

    Google Scholar 

  26. Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y (1989) Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun 1: 217–224

    Google Scholar 

  27. Garg LC, DiAngelo S, Jacob ST (1987) Role of DNA topoisomerase I in the transcription of supercoiled rDNA gene. Proc Natl Acad Sci USA 84: 3185–3188

    Google Scholar 

  28. Gasser SM, Laemmli UK (1986) Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes ofD. melanogaster. Cell 46: 521–530

    Google Scholar 

  29. Giaever GN, Wang JC (1988) Supercoiling of intracellular DNA can occur in eukaryotic cells. Cell 55: 849–856

    Google Scholar 

  30. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046–1048

    Google Scholar 

  31. Halligan BD, Edwards KA, Liu LF (1985) Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. J Biol Chem 260: 2475–2482

    Google Scholar 

  32. Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086–1090

    Google Scholar 

  33. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51: 4729–4731

    Google Scholar 

  34. Holm C, Goto T, Wang JC, Bolstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553–563

    Google Scholar 

  35. Holm C, Covey JM, Kerrigan D, Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365–6368

    Google Scholar 

  36. Hooper DC, Wolfson JS (1991) Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis 10: 223–231

    Google Scholar 

  37. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873–14878

    Google Scholar 

  38. Hsiang YH, Wu HY, Liu LF (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48: 3230–3235

    Google Scholar 

  39. Hsiang Y-H, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49: 4385–4389

    Google Scholar 

  40. Hsiang Y-H, Lihou MG, Liu LF (1989) Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082

    Google Scholar 

  41. Hsieh T (1983) Purification and properties of type II DNA topoisomerase from embryos ofDrosophila melanogaster. Methods Enzymol 100: 161–170

    Google Scholar 

  42. Huff AC, Ward RE, Kreuzer KN (1990) Mutational alterations of the breakage/resealing subunits of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. Mol Gen Genet 221: 27–32

    Google Scholar 

  43. Hwong C-L, Wang C-H, Chen Y-J, Whang-Peng J, Hwang J (1990) Induction of topoisomerase II gene expression in human lymphocytes upon phytohemagglutinin stimulation. Cancer Res 50: 5649–5652

    Google Scholar 

  44. Jaxel C, Kohn KW, Pommier Y (1988) Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res 16: 11157–11170

    Google Scholar 

  45. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465–1469

    Google Scholar 

  46. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266: 20418–20423

    Google Scholar 

  47. Jaxel C, Capranico G, Wasserman K, Kerrigan D, Kohn KW, Pommier Y (1991) DNA sequence at sites of topoisomerase I cleavage induced by camptothecin in SV40 DNA. In: Potmesil M, Kohn KW (eds) DNA topoisomerases in cancer. Oxford University Press. New York, pp 182–195

    Google Scholar 

  48. Johnson RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG (1989) SK&F 10864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc Am Assoc Cancer Res 30: 623

    Google Scholar 

  49. Juan CC, Hwang JL, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC, Liu LF (1988) Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q 12–13.2. Proc Natl Acad Sci USA 85: 8910–8913

    Google Scholar 

  50. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715–1720

    Google Scholar 

  51. Kaufmann SH (1989) Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870–5878

    Google Scholar 

  52. Kerrigan D, Pommier Y, Kohn KW (1987) Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. NCI Monogr 4: 117–121

    Google Scholar 

  53. Kim RA, Wang JC (1989) Function of DNA topoisomerases as replication swivels inSaccharomyces cerevisiae. J Mol Biol 208: 257–267

    Google Scholar 

  54. Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, Bolund L, Westergaard O (1988) Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 263: 3912–3916

    Google Scholar 

  55. Kreuzer KN (1989) DNA topoisomerases as potential targets of antiviral action. Pharm Ther 43: 377–395

    Google Scholar 

  56. Kunimoto T, Nitta K, Tanaka T, Uebuara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[1-piperidino)-l-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944–5947

    Google Scholar 

  57. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351–375

    Google Scholar 

  58. Long BH, Musial ST, Brattain MG (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 23: 1183–1188

    Google Scholar 

  59. Miller KG, Liu LF, Englund PT (1981) A homogeneous type II DNA topoisomerase from HeLa a cell nuclei. J Biol Chem 256: 9334–9339

    Google Scholar 

  60. Minford J, Pommier Y, Filipski J, Kohn KW, Kerrigan D, Mattern M, Michaels S, Schwartz R, Zwelling LA (1986) Isolation of intercator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry 25: 9–16

    Google Scholar 

  61. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase 1 clinical trial of weekly and daily treatment with camptothecin (NSC-100800): correlation with preclinical studies. Biochemistry 56: 515–521

    Google Scholar 

  62. Muller MT, Pfund WP, Mehta VB, Trask DK (1985) Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 4: 1237–1243

    Google Scholar 

  63. Muller MT, Spitzner JR, DiDonato JA, Mehta VB, Tsutsui K, Tsutsui K (1988) Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry 27: 8369–8379

    Google Scholar 

  64. Newport J, Spann T (1987) Disassembly of the nucleus in the mitotic extracts: membrane vesiculization, lamin disassembly, and chromosome condensation are independent processes. Cell 48: 219–230

    Google Scholar 

  65. O'Connor PM, Kerrigan D, Bertrand R, Kohn KW, Pommier Y (1990) 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Commun 2: 395–400

    Google Scholar 

  66. Osheroff N, Shelton ER, Brutlag DL (1983) DNA topoisomerase II fromDrosophila melanogaster. Relaxation of supercoiled DNA. J Biol Chem 258: 9536–9543

    Google Scholar 

  67. Pommier Y, Kohn KW (1989) Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: Glazer RI (ed) Developments in cancer chemotherapy. CRC Press, Boca Raton, Florida, pp 175–196

    Google Scholar 

  68. Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J, Bradley MO (1985) Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 45: 3143–3149

    Google Scholar 

  69. Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A (1986) Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075–3081

    Google Scholar 

  70. Pommier Y, Covey J, Kerrigan D, Mattes, W, Markovits J, Kohn KW (1987) Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem Pharmacol 36: 3477–3486

    Google Scholar 

  71. Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS, Whang-Peng J (1988) Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (CD3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res 48: 512–516

    Google Scholar 

  72. Pommier Y, Capranico G, Orr A, Kohn KW (1991) Distribution of topoisomerase II cleavage sites in SV40 DNA and the effects of drugs. J Mol Biol 222: 909–924

    Google Scholar 

  73. Pommier Y, Capranico G, Orr A, Kohn KW (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine and teniposide. Nucleic Acids Res 19: 5973–5980

    Google Scholar 

  74. Pommier Y, Jaxel C, Kerrigan D, Kohn KW (1991) Structure activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex. In: (eds) DNA topoisomerases in cancer. Oxford University Press, New York, pp 121–132

    Google Scholar 

  75. Porter SE, Champoux JJ (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17: 8521–8532

    Google Scholar 

  76. Priel E, Showalter SD, Blair DG (1991) Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses 7: 65–72

    Google Scholar 

  77. Riou J-F, Lefevre D, Riou G (1989) Stimulation of the topoisomerase II induced cleavage sites in thec-myc protooncogene by antitumor drugs is associated with gene expression. Biochemistry 28: 9104–9110

    Google Scholar 

  78. Roberge M, Th'ng J, Hamaguchi J, Bradbury EM (1990) The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells. J Cell Biol 111: 1753–1762

    Google Scholar 

  79. Ryan AJ, Squires S, Strutt HL, Johnson RT (1991) Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19: 3295–3300

    Google Scholar 

  80. Saulnier MG, Vyas DM, Langley DR, Doyle TW, Rose WC, Crosswell AR, Long BH (1989) E-ring desoxy analogues of etoposide. J Med Chem 32: 1418–1420

    Google Scholar 

  81. Schneider E, Lawson PA, Ralph RK (1989) Inhibition of protein synthesis reduces the cytotoxicity of 4′-(9-acridinylamino)methane-sulfon-m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line. Biochem Pharmacol 38: 263–269

    Google Scholar 

  82. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC (1986) High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231: 737–740

    Google Scholar 

  83. Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y (1988) DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res 48: 5096–5100

    Google Scholar 

  84. Sinha BK, Politi PM, Eliot HM, Kerrigan D, Pommier T (1990) Structure-activity relations, cytotoxicity and topoisomerase II dependent DNA cleavage induced by pendulum ring analogues of etoposide. Eur J Cancer 26: 590–593

    Google Scholar 

  85. Tamura H-O, Ikegami Y, Ono K, Sekimizu K, Andoh T (1990) Acidic phospholipids directly inhibit DNA binding of mammalian DNA topoisomerase I. FEBS Lett 261: 151–154

    Google Scholar 

  86. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466–468

    Google Scholar 

  87. Thurston LS, Irie H, Tani S, Han FS, Liu ZC, Cheng YC, Lee KH (1986) Antitumor agents: 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues. J Med Chem 29: 1547–1550

    Google Scholar 

  88. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177–7181

    Google Scholar 

  89. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M (1987) DNA topoisomerase II is required for condensation and separation of mitotic chromosomes inS. pombe. Cell 50: 917–925

    Google Scholar 

  90. Wall ME (1983) A new look at older drugs in cancer treatment: natural products. Biosci Rep 11: 480A-489A

    Google Scholar 

  91. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Slim GA (1966) The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor fromCamptotheca acuminata. J Am Chem Soc 88: 3888–3890

    Google Scholar 

  92. Wang H-P, Rogler CE (1991) Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 65: 2381–2392

    Google Scholar 

  93. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665–697

    Google Scholar 

  94. Wang JC (1987) Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1–9

    Google Scholar 

  95. Wang JC (1991) DNA topoisomerases: why so many? J. Biol Chem 266: 6659–6662

    Google Scholar 

  96. Wright SJ, Schatten G (1990) Teniposide, a topoisomerase II inhibitor, prevents chromosome condensation and separation but not decondensation in fertilized surf clam (Spisula solidissima) oocytes. Dev Biol 142: 224–232

    Google Scholar 

  97. Wu HY, Shyy SH, Wang JC, Liu LF (1988) Transcription generates positively and negatively supercoiled domains in the template. Cell 52: 433–440

    Google Scholar 

  98. Zhou B-Z, Bastow KF, Cheng Y-C (1989) Characterization of the 3′ region of the human DNA topoisomerase I gene. Cancer Res 49: 3922–3927

    Google Scholar 

  99. Zwelling LA, Hinds M, Chan D, Altschuler E, Mayes J, Zipf TF (1990) Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities towards monocytoid differentiation. Cancer Res 50: 7116–7122

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol. 32, 103–108 (1993). https://doi.org/10.1007/BF00685611

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685611

Keywords

Navigation